Driving tumor-associated macrophages to a CXCL9<sup>Hi</sup>/SPP1<sup>Low</sup> phenotype eliminates pancreatic cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42492520.
- Also identified by DOI 10.1016/j.xcrm.2026.102938.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with limited therapeutic options. Recent studies reveal the complex PDAC microenvironment, which fosters interactions between various cell types that contribute to immunosuppression. Among these, tumor-associated myeloid cells with a CXCL9-low, SPP1-high phenotype are particularly abundant and play a significant role in promoting disease progression. We hypothesize that targeting these cells can reprogram the tumor microenvironment and improve survival outcomes. To test this, we develop a myeloid cell-targeting nanoformulation, CANDI470, designed to increase CXCL9 expression and reduce SPP1 levels in tumor-associated myeloid cells. Our results demonstrate that this approach not only enhances immune responses but also achieves remarkable therapeutic efficacy, including cures in murine PDAC models, even when used as a monotherapy. This myeloid cell modulation strategy represents a promising therapeutic avenue for PDAC, offering hope for improved treatment for this otherwise difficult-to-treat malignancy.